Amgen

This study tests if Prolia can improve bone density in people whose bones have weakened from taking steroids (glucocorticoids). About 100 adults in China will receive the drug and be followed for 12 months. The main goal is to see if bone mass in the lower spine increases.

This study tests a new drug, maridebart cafraglutide, in 250 adults with obstructive sleep apnea who are overweight or obese and already use a breathing machine (PAP therapy). The goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss over 52 …

This study follows children and teenagers with osteogenesis imperfecta (brittle bone disease) who previously received the drug romosozumab in an earlier trial. The goal is to monitor their long-term safety by tracking any side effects. No new treatment is given—just observation. …

This study tests a drug called inebilizumab in children aged 2 to 17 with neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The goal is to see how the drug moves through the body, how safe it is, and whether it ca…

This study tests whether adding a new drug called xaluritamig to the standard drug abiraterone helps men with advanced prostate cancer live longer. The cancer has spread and no longer responds to hormone therapy, but participants have not yet had chemotherapy. About 750 men will …

This study allows people with advanced solid tumors who have a specific KRAS gene mutation (G12C) to keep receiving the drug sotorasib (alone or with panitumumab) after their original clinical trial ends. The goal is to monitor safety and side effects for those who are still bene…

This study tests a new drug called anvumetostat combined with other treatments for people with advanced gastrointestinal, bile duct, or pancreatic cancers that have a specific genetic change (MTAP deletion). The main goals are to find the safest dose and check for side effects. A…

This study tests a new treatment for older adults (55 and older, or 40+ with certain health issues) with a specific type of leukemia (ALL). The experimental approach combines a targeted drug called blinatumomab with low-intensity chemotherapy, and compares it to standard chemothe…

This study tests a new drug called maridebart cafraglutide in 180 adults who are overweight or obese and have high liver fat. Participants will receive the drug or a placebo, along with a reduced-calorie diet and more physical activity. The goal is to see if the drug safely reduc…

This study compares two first-line treatments for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and no PD-L1 protein. One group gets the targeted pill sotorasib plus chemotherapy; the other gets the immunotherapy pembrolizumab plus chemoth…

This study tests a drug called inebilizumab in 15 children aged 2 to 17 who have generalized myasthenia gravis, a disease that causes muscle weakness. The goal is to see how the drug moves through the body, how it affects immune cells, and whether it is safe. While the drug may h…

This study tests whether adding the experimental drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 adults who have not yet been treated will be randomly assigned to receive either the new com…

This early-stage trial is testing a new drug called xaluritamig in about 50 people with Ewing sarcoma, a rare bone cancer, that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also …

This study tests a new drug, maridebart cafraglutide, for adults with obstructive sleep apnea who are overweight or obese and not using a breathing machine (PAP therapy). Over 52 weeks, researchers will measure if the drug reduces breathing pauses during sleep and helps with weig…

This study tests whether the drug apremilast can reduce painful mouth ulcers in children aged 2 to 17 with Behçet's disease. About 60 children will receive either apremilast or a placebo for 12 weeks to see if the drug helps heal ulcers and reduce pain. The goal is to control the…

This study tests a new medicine called AMG 732 for people with moderate-to-severe active thyroid eye disease, a condition that can cause bulging eyes and discomfort. The trial has two parts: first, healthy volunteers receive a single dose to check safety; second, people with the …

This early-phase study tests a new drug called AMG 509 in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 479 participant…

This study tests if a shot under the skin (subcutaneous) of pegloticase works as well as the standard IV infusion for people with uncontrolled gout. Both groups also take methotrexate weekly. The goal is to lower uric acid levels below 6 mg/dL for most of the sixth month. About 2…

This study tests a drug called etelcalcetide in 24 children aged 2 to 17 who have overactive parathyroid glands (secondary hyperparathyroidism) and are on kidney dialysis. The goal is to see if the drug safely lowers parathyroid hormone levels, which can help control bone and min…

This study tests a new, easier way to give the drug blinatumomab—as a shot under the skin—for people with a tough-to-treat leukemia called B-ALL. The trial includes adults and teens whose cancer has come back or not responded to other treatments. The goal is to see if the shot is…

This early-phase study tests a new drug, AMG 410, in people with advanced or spreading solid tumors that have a specific change in the KRAS gene. The main goals are to check safety, find the best dose, and see if the drug works alone or with other treatments. About 434 adults who…

This study tests whether a new drug, maridebart cafraglutide, can reduce the risk of heart attacks, strokes, and heart-related death in people who have heart disease and are overweight or obese. About 12,800 adults aged 45 and older will receive either the drug or a placebo, alon…

This study tests whether adding the drug avacopan to standard treatments (rituximab or cyclophosphamide) can help children aged 6 to 17 with active ANCA-associated vasculitis (AAV) achieve remission. AAV is a rare disease where the immune system attacks small blood vessels, causi…

This study tests a drug called olpasiran in people with stable heart disease and high levels of lipoprotein(a), a genetic risk factor. The goal is to see if olpasiran can reduce non-calcified plaque in the heart arteries compared to a placebo over 72 weeks. About 406 adults aged …

This study tests whether a new drug called ABP 692 works as well as the approved drug Ocrevus for people with relapsing-remitting multiple sclerosis (RRMS). About 444 adults with RRMS will receive either ABP 692 or Ocrevus to compare how the drugs move through the body and how we…

This early-stage trial tests a new drug called xaluritamig combined with standard hormone therapies (darolutamide or abiraterone) in 60 men with metastatic hormone-sensitive prostate cancer that has spread. The main goal is to check safety and side effects, while also measuring h…

This study tests a new drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has come back after chemotherapy. The main goals are to see if it is safe and to measure how the body handles the drug. About 220 adults will…

This study tests whether adding two targeted drugs (sotorasib and panitumumab) to standard chemotherapy helps people with a specific genetic form of metastatic colorectal cancer live longer without their cancer growing. About 450 people who have not had prior treatment for their …

This study tests a new drug called anvumetostat in people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a missing MTAP gene. The goal is to see if the drug can shrink tumors or slow cancer growth. About 200 adults who have already tried at least one…

This study tests whether the drug apremilast can help children aged 5 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and skin problems. About 60 kids will receive either the drug or a placebo for 16 weeks. The main goal is to see if apremilast redu…

This study looks at the long-term safety of the drug apremilast in children aged 2 and older with Behçet's disease (which causes painful mouth sores) or aged 5 and older with juvenile psoriatic arthritis (a type of arthritis). About 48 kids who finished a previous study will take…

This study tests a drug called romosozumab against standard bone-strengthening medicines (bisphosphonates) in 106 children and teens with osteogenesis imperfecta, a condition that causes fragile bones and frequent fractures. The goal is to see if romosozumab reduces the number of…

This early-phase study tests a new drug called anvumetostat, alone or with other therapies, in adults with advanced chest tumors (like lung cancer) that have a specific genetic change (MTAP deletion). The main goals are to find the safest dose and check for side effects. About 50…

This study tests a new drug, maridebart cafraglutide, in about 5,000 adults with heart failure and obesity. The goal is to see if it reduces heart failure events like hospitalizations and improves symptoms. Participants receive the drug or a placebo alongside standard care.

This study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who are newly diagnosed or have a relapse will take either avacopan or a placebo. The m…

This early-phase study tests a new drug called AMG 436, alone or with other cancer treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goals are to check the drug's safety and find the best dose. About 464 adults with thes…

This study looks at the long-term safety of the drug dazodalibep in people with Sjögren's syndrome. About 844 participants who completed a previous phase 3 study will receive the drug and be monitored for side effects and immune responses. The goal is to see if the drug remains s…

This early-stage trial tests a combination of two drugs, tarlatamab and ZL-1310, with or without a third drug (durvalumab) in people with small cell lung cancer that has come back after standard treatment. The main goal is to find safe doses and check for side effects. About 160 …

This study looks at whether adding Repatha® to usual care lowers the risk of major heart problems like heart attacks, strokes, and heart-related death in Chinese adults with established heart disease. About 7,000 participants will be followed to compare those getting Repatha® plu…

This early-stage trial tests two experimental drugs, tarlatamab and AB248, together in people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The main goal is to see if the combination is safe and to find the best dose. About 380 …

This study tests a new drug called xaluritamig, given alone or with hormone therapy, before prostate removal surgery in men with intermediate or high-risk prostate cancer. The goal is to see if the drug is safe and if surgery afterward is still possible. About 40 men will take pa…

This early-stage study tests whether a new drug, maridebart cafraglutide, can help people with type 2 diabetes use insulin better. About 70 adults with diabetes who are already taking metformin will receive either the new drug or a placebo. The main goal is to see if the drug imp…

This study tests a drug called etelcalcetide in children aged 28 days to under 18 years who have chronic kidney disease and are on dialysis. The goal is to see if it can safely lower high levels of parathyroid hormone, a common complication. About 56 participants will receive eit…

This study tests a subcutaneous (under-the-skin) shot of blinatumomab in children under 12 with relapsed/refractory or minimal residual disease positive B-cell acute lymphoblastic leukemia. The goal is to see if the shot is safe and helps achieve remission. About 104 children wil…

This study compares a new drug, xaluritamig, with two standard treatments (cabazitaxel or another hormone therapy) in 675 men with metastatic castration-resistant prostate cancer that has worsened after chemotherapy. The main goal is to see if xaluritamig helps patients live long…

This early-stage study tests a new drug called AMG 513 in people with obesity. The main goal is to see if it is safe and how the body handles it. About 80 adults with a body mass index (BMI) between 27 and 40 will take part. The study will look at side effects and how the drug mo…

This study tests two medications, inebilizumab and blinatumomab, in adults with hard-to-treat lupus or rheumatoid arthritis. The goal is to see if these drugs are safe and can help control disease activity. About 220 participants will receive the drugs by injection or infusion. T…

This study is testing whether a drug called olpasiran can prevent first major heart problems like heart attacks in people who have high levels of a specific blood fat called lipoprotein(a). It will involve 11,000 participants aged 50+ who have high lipoprotein(a) and other heart …

This early-stage study is testing a new drug called AMG 691 to see if it is safe and how the body processes it. The study includes healthy volunteers and people with mild-to-moderate asthma. Participants will receive either the drug or a placebo, and researchers will monitor for …

This study tests how the body handles two different forms of evolocumab, a drug used to lower cholesterol. About 400 healthy adults aged 18 to 60 will receive a single dose and be monitored for drug levels and side effects. The goal is to compare the two versions, not to treat an…

This study is for pregnant women with migraine who have taken the drug AIMOVIG (erenumab-aooe) during pregnancy. Researchers will compare their babies' health, especially birth defects, to babies born to women with migraine who did not take the drug. The goal is to better underst…

This early-stage study looks at how a new weight-loss drug, maridebart cafraglutide (AMG 133), changes the way the body processes oral contraceptives. It involves 45 postmenopausal women aged 45 to 65 who are overweight or obese. The goal is to see if the drug affects birth contr…

This study follows 60 women with neuromyelitis optica spectrum disorder (NMOSD) who received UPLIZNA during pregnancy or within six months before conceiving. Researchers will collect data on pregnancy outcomes, including birth defects, preterm birth, and infant development over 1…